Invesaro

Stocks Industrials BIO

NYSE · Industrials

Bio-Rad Laboratories, Inc. (BIO)

Bio-Rad Laboratories, Inc. brought in $2.6B of revenue over the twelve months to June 30, 2026, up 1.4% from a year earlier. Net income was $222.4M, a net margin of 8.6%. Operating cash flow minus capital spending left $374.6M of free cash flow in fiscal 2025. At June 30, 2026 it held $517M in cash against $1.2B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.

Price
$381.00
-1.69% on the day · September 25, 2026
52-week range $236.73 to $396.23
Market cap
$10.2B
Revenue (last 12 months)
$2.6B
+1.4% year on year
Net margin
8.6%
P/E
13.7
on FY2025 diluted EPS

What Bio-Rad Laboratories, Inc. does

Bio-Rad Laboratories, Inc. is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NYSE under the ticker BIO.

Revenue and profit by year

Revenue
FY18: $2.3B $2.3B FY18FY19: $2.3B $2.3B FY19FY20: $2.5B $2.5B FY20FY21: $2.9B $2.9B FY21FY22: $2.8B $2.8B FY22FY23: $2.7B $2.7B FY23FY24: $2.6B $2.6B FY24FY25: $2.6B $2.6B FY25
Net income
FY18: $365.6M $365.6M FY18FY19: $1.8B $1.8B FY19FY20: $3.8B $3.8B FY20FY21: $4.3B $4.3B FY21FY22: -$3.6B -$3.6B FY22FY23: -$637.3M -$637.3M FY23FY24: -$1.8B -$1.8B FY24FY25: $759.9M $759.9M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$2.6B$47.2M$759.9M$27.85$374.6M
2024$2.6B$269M-$1.8B-$65.36$289.6M
2023$2.7B$337.8M-$637.3M-$21.82$218.2M
2022$2.8B$482.6M-$3.6B-$121.79$81.6M
2021$2.9B$500.3M$4.3B$140.83$535.7M
2020$2.5B$421.3M$3.8B$126.47$476.4M

Latest SEC filings

What Bio-Rad Laboratories, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 4, 2026
    Quarterly report 10-Q · period to June 30, 2026
  2. August 4, 2026
    Quarterly results 8-K
  3. May 13, 2026
    Conflict minerals disclosure SD
  4. April 30, 2026
    Employee stock plan registration S-8
  5. April 30, 2026
    Quarterly report 10-Q · period to March 31, 2026
  6. April 30, 2026
    Quarterly results 8-K
  7. April 24, 2026
    Executive or director change 8-K
  8. March 26, 2026
    Passive stake changed SCHEDULE 13G/A
  9. March 25, 2026
    Annual report to shareholders ARS
  10. March 25, 2026
    Proxy statement DEF 14A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 9, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about BIO

What does Bio-Rad Laboratories, Inc. do?

Bio-Rad Laboratories, Inc. is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NYSE under the ticker BIO.

Is Bio-Rad Laboratories, Inc. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $222.4M on revenue of $2.6B, a net margin of 8.6%.

How much revenue does Bio-Rad Laboratories, Inc. make?

Over the twelve months to June 30, 2026 Bio-Rad Laboratories, Inc. reported revenue of $2.6B. That is 1.4% more than a year earlier.

When did Bio-Rad Laboratories, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 9, 2026.

Similar companies

A
Agilent Technologies, Inc.
AVTR
Avantor, Inc.
ILMN
Illumina, Inc.
MTD
Mettler Toledo International Inc/
BRKRP
Bruker Corp
WAT
Waters Corp

Follow BIO

Get an email when Bio-Rad Laboratories, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow BIO: get an email when it files

Where the numbers come from

Financial figures are the values Bio-Rad Laboratories, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.